Evaxion presented new preclinical data for its AI-designed cytomegalovirus (CMV) vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026. The data show that EVX-V1's multi-component approach, combining novel AI-discovered antigens with optimized known antigens, enhances control over acute infection, latency, and viral reactivation in preclinical models. This progress is significant as no licensed CMV vaccine currently exists, despite the virus causing severe disease in immunocompromised patients and infants. The company plans to use these findings to guide antigen selection for further vaccine development, potentially transforming CMV treatment.
Investor Brad Thomas reviews his worst REIT investments—ARCP, MPW, SAFE, and IIPR—to highlight critical lessons learned. He stresses that broken trust and poor management can destroy value despite attractive yields, as seen with ARCP. The risks of ch...
Evercore has upgraded Occidental Petroleum (OXY) citing better capital efficiency and successful debt reduction. This upgrade reflects growing optimism driven by expectations of sustained higher commodity prices, supported by positive ratings from bo...
Helus Pharma receives a speculative Buy rating due to its lead drug HLP003, an oral treatment for major depressive disorder showing promising Phase 2 results and FDA Breakthrough Therapy status. The company’s current valuation undervalues HLP003’s po...
A New York legal case, Noah Doe, claims ownership of 39,069 dormant Bitcoin addresses valued at $293 billion under abandoned property laws. This challenges the core principle of Bitcoin self-custody, which relies on private keys, not inactivity, to p...
BlackRock's USD Institutional Digital Liquidity Fund (BUIDL) on Avalanche surged past $900 million in assets, doubling from about $464 million in just one week. This rapid growth reflects increasing institutional demand for tokenized U.S. Treasury as...
